Table 4 Gene usage of anti-V3 scFvs
From: A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C
scFv | VH | Â | Â | VL | Â |
|---|---|---|---|---|---|
| Â | V | D | J | V | J |
1D5C | IGHV3-23*04 | IGHD3-10*01 | IGHJ3*02 | IGKV3-20*01 | IGKJ1*01 |
1E7B | IGHV4-31*03 | IGHD5-24*01 | IGHJ6*03 | IGKV3-20*01 | IGKJ2*01 |
1G8C | IGHV5-51*01 | IGHD4-11*01 | IGHJ5*02 | IGKV2-28*01 | IGKJ2*01 |
3B2C | IGHV5-51*01 | IGHD4-11*01 | IGHJ5*02 | IGKV1-5*03 | IGKJ4*01 |
3B6C | IGHV4-b*02 | IGHD3-10*02 | IGHJ4*02 | IGKV1-39*01 | IGKJ2*02 |
3B7C | IGHV4-b*02 | IGHD3-10*02 | IGHJ1*01 | IGKV3-20*01 | IGKJ4*01 |
3C3C | IGHV5-51*01 | IGHD4-11*01 | IGHJ5*02 | IGKV3-20*01 | IGKJ1*01 |
3E6C | IGHV4-59*08 | IGHD3-10*02 | IGHJ1*01 | IGKV1-12*02 | IGKJ3*01 |
3E6B | IGHV4-b*02 | IGHD3-10*02 | IGHJ4*02 | IGKV1-39*01 | IGKJ4*01 |
3E7B | IGHV5-51*01 | IGHD4-11*01 | IGHJ5*02 | IGKV3-20*01 | IGKJ1*01 |